The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Resection and Liver Transplantation for Hepatocellular Carcinoma
Abstract
Surveillance programs in cirrhotic patients enable the detection of hepatocellular carcinoma (HCC) at early stages, when the tumor is amenable to curative treatments (60% of cases in Japan; 25 to 40% in Europe and the United States). Resection is the mainstay of treatment in noncirrhotic patients and in cirrhotics with well-preserved liver function. In modern series, a perioperative mortality < or = 3% and 5-year survival rates above 50% are expected. Tumor recurrence complicates half of the cases at 3 years, but there is no unquestionable preventive treatment. Liver transplantation provides excellent outcomes applying the Milan criteria (single nodule < or = 5 cm or two or three nodules < or = 3 cm), with 5-year survival rates of 70% and low recurrence rates. Although expansion of selection criteria is appealing, it should be assessed in the setting of prospective well-designed studies. Intention-to-treat analysis has shown that wide extended indications lead to 25% 5-year survival rates. Living donor liver transplantation is having a minor impact in HCC management. Molecular markers are needed to better select the candidates for surgery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [27]
Citations
Cites
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186 · cited 2×
“, Milan criteria).(19) Knowledge of tumor biology has not improved in parallel with clinical advancement.”
BackgroundSelf-citationClinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationEstimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Self-citationLlovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029 · cited 2×
“Several other treatments have not shown any relevant survival benefit (immunotherapy, internal radiation, tamoxifen, or antiandrogen agents) or are currently under investigation (tyrosine kinase inhibitors, antiangiogenic agents, gene therapy).(35) Table 1 Evidence-Based Benefits in the Treatment of Hepatocellular Car…”
BackgroundSelf-citationLlovet, J. M., Fuster, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510300629 · Cited by 1,708 · cited 4×
“The BCLC group identified the absence of clinically relevant portal hypertension and normal bilirubin as the key variables to select the best candidates, so-called ChildPugh hyper A patients.(11,57) A hepatic venous pressure gradient > 10 mm Hg was shown to be a predictor of unresolved hepatic decompensation after sur…”
BackgroundInfluentialSelf-citationAmerican Joint Committee On Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88443-1 · Cited by 1,386
Llovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510290145 · Cited by 1,190 · cited 2×
“6).(7) Treatment of HCC to reduce waiting list dropout has become a priority at most centers (Fig.”
BackgroundSelf-citationPrognostic prediction and treatment strategy in hepatocellular carcinoma
Bruix, J., & Llovet, J. M. (2002) · Hepatology · doi:10.1053/jhep.2002.32089 · Cited by 1,099
Self-citationBelghiti, J., Hiramatsu, K., Benoist, S., Massault, P. P., Sauvanet, A., & Farges, O. (2000) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(00)00261-1 · Cited by 1,051
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Some centers have reported zero peri-operative mortality [176,183].”
BackgroundInfluentialForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Self-citationEl-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Self-citationMazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., Camerini, T., Roayaie, S., Schwartz, M. E., Grazi, G. L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70284-5 · Cited by 2,045
Self-citation
Metadata
- Authors
- Llovet, J. M., Schwartz, M., & Mazzaferro, V.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Mount Sinai Hospital (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2005-05
- Volume
- 25
- Issue
- 02
- Pages
- 181-200
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W1990073288
- Cited by
- 879
- References
- 84
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 23 · 2023: 18 · 2022: 28 · 2021: 32 · 2020: 44 · 2019: 52 · 2018: 48 · 2017: 51 · 2016: 60 · 2015: 66 · 2014: 70 · 2013: 66 · 2012: 47
- FWCI
- 26.04
- Type
- journal article
- Language
- de
- Open access
- closed
- Locations
- Seminars in Liver Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K24DK060498, K24 DK 60498-01)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, hepatectomy, liver transplantation, Milan criteria, liver cirrhosis, tumor recurrence, extended indications, living donor liver transplantation, molecular markers, surgical selection, perioperative mortality, survival outcomes
- MeSH terms
- Hepatectomy, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Liver Neoplasms, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Survival Analysis, Liver Transplantation, Chemoembolization, Therapeutic, Chemotherapy, Adjuvant, Patient Selection, Living Donors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resection and Liver Transplantation for Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1055/s-2005-871198
- The paper
- Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005). Resection and Liver Transplantation for Hepatocellular Carcinoma. Seminars in Liver Disease. https://doi.org/10.1055/s-2005-871198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.